Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH3051 in advanced solid tumors
NCT04423380Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sh3051 in solid tumor, sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 28 days and Incidence of Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
sh3051
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04423380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423380.